Document Detail


Neonatal screening for congenital hypothyroidism: results and perspectives.
MedLine Citation:
PMID:  9251921     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Systematic screening for congenital hypothyroidism in the neonate constitutes a major progress in the prevention of mental retardation, as the condition occurs in 1/4,000 newborns and necessarily results in brain damage if not properly detected and treated during the first days of life. Screening and diagnostic and therapeutic procedures are discussed, as well as outcome and prognosis of the affected infants. Primary thyroid-stimulating hormone screening is almost universally recommended. Early therapy (within 14 days) with appropriate doses of thyroxine (about 10 micrograms/kg/day) will prevent any brain damage even in case of evidence of fetal hypothyroidism, as thyroxine of maternal origin will reach the fetus and largely protect him. Neonatal thyroid screening is also a particularly sensitive monitoring tool in the evaluation of the effects and of the correction of iodine deficiency at the population level.
Authors:
F Delange
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Hormone research     Volume:  48     ISSN:  0301-0163     ISO Abbreviation:  Horm. Res.     Publication Date:  1997  
Date Detail:
Created Date:  1997-10-09     Completed Date:  1997-10-09     Revised Date:  2005-11-17    
Medline Journal Info:
Nlm Unique ID:  0366126     Medline TA:  Horm Res     Country:  SWITZERLAND    
Other Details:
Languages:  eng     Pagination:  51-61     Citation Subset:  IM    
Affiliation:
Department of Pediatrics, University Hospital Saint-Pierre, Brussels, Belgium. fdelange@ulb.ac.be
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Child
Child, Preschool
Congenital Hypothyroidism*
Humans
Hypothyroidism / complications,  drug therapy,  etiology
Infant
Infant, Newborn
Mass Screening*
Mental Retardation / etiology,  prevention & control*
Prognosis
Thyrotropin / blood
Thyroxine / administration & dosage,  blood,  therapeutic use
Chemical
Reg. No./Substance:
7488-70-2/Thyroxine; 9002-71-5/Thyrotropin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Adenosine receptor agents and conditioned place preference.
Next Document:  Factors determining pubertal growth and final height in growth hormone treatment of idiopathic growt...